Michael Morabito
Stock Analyst at Chardan Capital
(0.04)
# 4,126
Out of 4,667 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $30.64 | +164.40% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $317.09 | -35.98% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.90 | +8,753.47% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $7.98 | +1,090.48% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $51.53 | -61.19% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $30.64
Upside: +164.40%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $317.09
Upside: -35.98%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.90
Upside: +8,753.47%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $7.98
Upside: +1,090.48%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $51.53
Upside: -61.19%